A 6-week, Multi-centre, Randomised, Double-blind (Participant and Investigator), Placebo-controlled, Dose-finding Trial to Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral BI 1569912 in Patients With Major Depressive Disorder
Latest Information Update: 23 May 2025
At a glance
- Drugs BI 1569912 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 16 May 2025 Status changed from active, no longer recruiting to completed.
- 18 Mar 2025 Planned End Date changed from 20 May 2025 to 7 May 2025.
- 18 Mar 2025 Planned primary completion date changed from 12 May 2025 to 25 Apr 2025.